Latest News
- June 21, 2024First patient randomized in a Phase 1 study for a China based Biotech Company
- May 28, 2024IND application submitted by CBCC
- May 17, 2024We are exhibiting at BIO 2024! Come visit our booth #4952
- May 16, 2024Let’s connect at 2024 ASCO annual meeting!
- May 09, 2024Successful completion of 9 USFDA inspections
January 07, 2024
We welcome Dr David Bearss to our strategic advisory board
We are pleased to announce the induction of David Bearss Ph.D. to our strategic advisory board as a key advisor for clinical trials.
Dr. David Bearss is the CEO of Halia Therapeutics, Inc. He is an experienced entrepreneur and drug developer with 20 plus years of experience in academic and industry settings.
We are confident that Dr. Bearss’ comprehensive understanding of the drug development life cycle and technical expertise in all aspects of patient care will add immeasurable value to our Customer’s Clinical Development Plans.
CBCC Global Research: CHANGING LIVES THROUGH HOPE AND INNOVATION